Curetopia has secured $1.77 million in funding to expedite treatments for rare diseases through a decentralized biotech model leveraging Solana.
The fundraising effort, supported by more than 1,000 individual contributors, highlights growing momentum in the decentralized science (DeSci) sector, particularly amid a sustained US freeze on traditional funding sources like the National Institutes of Health (NIH) and National Science Foundation (NSF).
The Curetopia DAO, launched on Bio Protocol with backing from Binance seeks to address an estimated $1 trillion rare disease market historically underserved by large pharmaceutical companies. Utilizing blockchain-based crowdfunding, Curetopia enables rare disease patients and researchers to collaboratively finance drug development projects, sharing ownership of resulting treatments through tokenization.
Curetopia recently identified a potential treatment for AARS2 progressive leukoencephalopathy, a fatal mitochondrial disease lacking any approved therapies. This discovery, arising from screening 8,500 repurposable compounds via yeast models, represents one of the first instances of a crypto-backed research project potentially reaching commercialization.
Curetopia is currently filing a provisional patent for this discovery. Any proceeds from subsequent commercialization will be reinvested into the DAO.
Curetopia’s operational model incorporates direct engagement with patient communities, a strategy championed by founder Dr. Ethan Perlstein, a Harvard PhD and former Y Combinator participant. Perlstein previously demonstrated cost-effective clinical development by advancing a rare disease treatment to Phase 3 trials for $5 million—markedly lower than traditional pharmaceutical pathways.
Perlstein emphasized that decentralized drug development empowers rare disease patients and families to directly influence therapeutic development, breaking the cycle of neglected research due to limited commercial incentives.
Participants in Curetopia’s decentralized trials receive CURES tokens, effectively becoming stakeholders in the therapies they help develop.
Curetopia’s model, which leverages drug repurposing, tokenized intellectual property, and community-driven trials, seeks to accelerate regulatory approval processes, significantly reducing both time and financial costs relative to conventional drug development.
The DAO also recently partnered with COMBINEDBrain and Unravel Biosciences to provide drug screening services to organizations representing more than 100 genetic neurodevelopmental disorders.
With a focus on drug repurposing, Curetopia aims to capitalize on regulatory advantages such as FDA Priority Review Vouchers and Orphan Drug Designation, which offer expedited pathways and incentives for rare disease therapeutics.
